Vyepti : Eptinezumab

Vyepti : Eptinezumab 🔘Monoclonal antibody 🔘CGRP inhibitor 🔘migraine prevention 🔘Dose: 100 mg IV infusion Q3 months to max 300mg  🔘Does not produce toxins as it undergoes proteolysis. 🔘Half-life is 27 days. 🔘Side effects: URI, UTI, ARthralgia, Fatigue, back pain, N, Vomiting, Nasopharyngitis, and , facial flushing, rash, hypersensitive reaction, angioedema. 🔘No adjustment needed for renal or hepatic dysfunction but for pregnancy and lactation caution is advised

Leave a Reply

Your email address will not be published. Required fields are marked *